Deloxolone was devoid of aldosterone-like properties. Deloxolone could be of therapeutic value in peptic ulcer diseases without inducing fluid retention, hypertension and hypokaliemia. Carbenoxolone and deloxolone were orally administered to healthy volunteers in a cross-over double-blind trial. Both the concentration in gastric juice and the output of PGE2, determined by an RIA method in basal conditions and after pentagastrin bolus, increased in drug-treated compared to vehicle-treated subjects thus supporting the hypothesis that cytoprotection might be due to gastric PGE, levels. Moreover, deloxolone induced less marked effects than carbenoxolone on body weight, hematocrit, plasma potassium and proteins, confirming that deloxolone is less similar to aldosterone than the reference drug.

Levopropylcillin – is a penicillin derivative, L-enantiomer of antibiotic Propicillin. Levopropylcillin properties are similar to benzylpenicillin particularly used in streptococcal infections, not resistant to penicillinase. Levopropylcillin is acid resistant and can be used orally as the potassium salt.

ITROCINONIDE is a synthetic corticosteroid which showed no signs of systemic activity (cortisol depression).

Imagabalin is a ligand to the α(2)δ subunit of voltage-sensitive calcium channel and was developed to treat generalized anxiety disorder. Imagabalin was involved in phase III clinical trials when was made a decision to terminate all studies. However, this decision was not based on any safety concerns.

Imcarbofos is diphosphoricthioamide derivative patented by American Cyanamid Co as anthelmintics agent.

Pleuromulin (pleuromulitin) is a natural antibiotic isolated from Basidiomycete Pleurotus. Pleuromulitin exhibits activity mainly against gram-positive bacteria including S. aureus, Klebasiella pneumoniae and Bacillus Subtilis. Pleuromulin is an organic compound which is not reported to be used in as a drug however its derivatives have been used in treatment of infections. The first pleuromulitin that was approved in 1979 for use in veterinary medicine was semi-synthetic derivative tiamulin. Semisynthetic pleuromutilin retapamulin (ALTABAX, GlaxoSmithKline) was the first approved for topical use in humans in 2007. Another derivative of pleuromulin, Lefamulin has been successfully tested in phase 1 clinical trial for systemic use in patients (Nabriva Therapeutics AG).

Pinolcaine is 10-methyl-2-substituted piperidine. Pinolcaine is a local anesthetic.

Mivobulin is a synthetic water-soluble colchicine analog with the broad antitumor activity that competitively binds tubulin at the colchicine-binding site and inhibits tubulin polymerization. Cancer cells exposed to Mivobulin isethionate accumulate in the M phase of the cell cycle and subsequently die. Preclinical studies have demonstrated that Mivobulin isethionate is able to cross the blood-brain barrier. Importantly, Mivobulin isethionate demonstrated significant antitumor activity in a broad spectrum of murine and human tumor models that were cross-resistant to vincristine, cisplatin, vinblastine, navelbine, and doxorubicin and in tumor cell lines exhibiting multidrug resistance owing to P-glycoprotein overexpression. In animal studies, the activity of Mivobulin isethionate was largely independent of the route of drug administration but favored a prolonged treatment schedule. Unfortunately, in clinical trials, Mivobulin fail to demonstrate the significant activity